Kisunla TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: donanemab
Pack: Kisunla 350 mg/20 mL injection, 20 mL vial
Brand name
(ARTG)
: KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vialConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
KISUNLA is indicated for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimers disease and Mild Alzheimers dementia (Early Symptomatic Alzheimers disease) that are apolipoprotein E Epsilon4 (ApoE Epsilon4) heterozygotes or non-carriers. Beta amyloid evidence consistent with Alzheimers disease (AD) should be confirmed using a validated test prior to initiating treatment.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, concentrated
- Intravenous Infusion
- Clear to opalescent, colourless to slightly yellow to slightly brown solution, free of visible particles.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Refrigerate
- Do not Shake
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient donanemab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
